SCHEMBL866289

SCHEMBL866289

COC(=O)N1CCCC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
KMT2A Q03164 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPT P10636 2/20 0.51
MEN1 O00255 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
THRB P10828 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
RECQL P46063 1/20 0.51
BLM P54132 1/20 0.51
BRD4 O60885 1/20 0.41
BRD2 P25440 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
CASP6 P55212 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
STAT6 P42226 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4939722 0.94 LMNA (0.47) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL27731125 0.83 LMNA (0.57) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL28285589 0.81 LMNA (0.55) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL1231766 0.80 LMNA (0.55) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL1284277 0.79 LMNA (0.53) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL10532645 0.79 LMNA (0.53) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL28043565 0.79 LMNA (0.53) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL4534739 0.79 LMNA (0.48) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL10653095 0.79 LMNA (0.48) LMNAKMT2AKDM4EMAPTMEN1
SCHEMBL205421 0.79 LMNA (0.48) LMNAKMT2AKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105294700-A Preparation method for tert-butyl dioxy-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid SHANGHAI SYNTHEALL PHARMACEUTICAL CO LTD 2016-02-03 CN claimed
CN-103509012-A Phenanthroindolizidine alkaloid C14-site aminated derivatives, and preparation and anti-plant virus activity thereof UNIV NANKAI 2014-01-15 CN claimed
CN-102250014-B Method for preparing chiral 1-benzyloxycarbonyl hexahydropyridazine-3-carboxylic acid and chiral 1, 2-dibenzyloxycarbonyl hexahydropyridazine-3-carboxylic acid SHANGHAI AOBO BIO PHARMACEUTICAL TECH CO LTD 2013-11-13 CN claimed
CN-1946772-B Dendritic polymers with enhanced amplification and internal functionality DENDRITIC NANOTECHNOLOGIES INC 2013-01-02 CN claimed
CN-101443048-B Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES INC 2013-01-02 CN claimed
CN-102250014-A Method for preparing chiral 1-benzyloxycarbonyl hexahydropyridazine-3-carboxylic acid and chiral 1, 2-dibenzyloxycarbonyl hexahydropyridazine-3-carboxylic acid SHANGHAI AOBO BIO PHARMACEUTICAL TECH CO LTD 2011-11-23 CN claimed
EP-2385078-A1 Dendritic polymers with enhanced amplification and interior functionality Dendritic Nanotechnologies Inc. (US) 2011-11-09 EP claimed
US-20110254461-A1 Power adaptors HOLDIP LIMITED (GB) 2011-10-20 US claimed
US-7985424-B2 Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES INC. (US) 2011-07-26 US claimed
US-7981444-B2 Dendritic polymers with enhanced amplification and interior functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2011-07-19 US claimed
EP-1737899-A4 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES INC (US) 2008-03-05 EP claimed
EP-1877103-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY Dendritic Nanotechnologies, Inc. (US) 2008-01-16 EP claimed
US-20070298006-A1 Dendritic Polymers With Enhanced Amplification and Interior Functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2007-12-27 US claimed
US-20070244296-A1 Dendritic Polymers with Enhanced Amplification and Interior Functionality DENDRITIC NANOTECHNOLOGIES, INC. (US) 2007-10-18 US claimed
CN-1946772-A Dendritic polymers with enhanced amplification and internal functionality DENDRITIC NANOTECHNOLOGIES INC (US) 2007-04-11 CN claimed
EP-1737899-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY Dendritic Nanotechnologies, Inc. (US) 2007-01-03 EP claimed
WO-2006065266-A9 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES INC (US) 2006-12-21 WO claimed
WO-2006115547-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES, INC. (US) 2006-11-02 WO claimed
WO-2006065266-A2 DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY DENDRITIC NANOTECHNOLOGIES, INC. (US) 2006-06-22 WO claimed
US-5266306-A Cetylpyridinium chloride and n-acyl basic amino acid alkyl ester; bactericide, anticaries, antiplaque agents SUNSTAR KABUSHIKI KAISHA (JP) 1993-11-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070298006-A1 Dendritic Polymers With Enhanced Amplification and Interior Functionality MYD88, TLR3, TMEM97 LMNA 1465/4885KMT2A 2627/4885KDM4E 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.